Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
(4) - EconoTimes)
KING OF PRUSSIA, Pa., May 31, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of May 22, 2017 and May 30, 2017, the grant of inducement stock options to purchase an aggregate of 100,000 shares of the Company’s common stock to two new employees. These awards were granted pursuant to the Trevena, Inc. Inducement Plan as an inducement material to the new employees entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4).
The first stock option, for 47,500 shares, has an exercise price per share of $2.98, the closing stock price on May 22, 2017; the second stock option, for 52,500 shares, has an exercise price per share of $2.40, the closing stock price on May 30, 2017. Each option has a ten-year term and will vest with respect to one-fourth of the total number of shares subject to the option on each of first, second, third, and fourth anniversaries of the grant date.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in early clinical development for the treatment of migraine, and TRV734 for pain. The Company maintains an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Vice President, Corporate Strategy & Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
